Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Post by Montevialeon Nov 02, 2017 8:35pm
228 Views
Post# 26898054

Linton Webinar earlier today...

Linton Webinar earlier today...I had an opportunity to listen to Linton's webinar today with Alan Brochstein...

For those who dont want to listen to the hour long interview, I would suggest you jump to the 42 minute mark where he discusses pharmacies followed by the TMX / Aphria issue.  

He does not see pharmacies becoming part of the medical distribution channel until after 2018.  He believes that Shoppers made a lot of noise when they first applied and then quietly disappeared.  So according to Linton, don't expect pharmacies to become part of the medical distribution channel anytime soon.   

He then discussed the Aphria / TMX issue right after the Shoppers question.  He seems to be conceeding that the issue will be resolved in Aphria's favour and it will be business as "unusual" because he still maintains that Aphria is breaking the law and "enhanced disclosure" should not remedy the situation.  He still can't get his head wrapped around the CSA and OSC's decsion to allow "enhanced disclosure" as part of the test for doing business in the US.  

What I did find surprising is thet he toned down his criticism of Aphria doing business in the US, conceeding that the "Cole" memo will most likely be included in legislation passed by Congress in December and that nothing will be done and it will be business as "unusal".   I can't help but think partnering with CB might have softened his position on doing business in the US, even if it was only a small shift.  It will be interesting going forward to watch how he now handles the issue of doing business in the US now that he has a US business partner.  

M
Bullboard Posts